DINESH

Global Health

Industry: Healthcare
Latest CMP 1,423
Today's Change ▲ 0.90%
52-Week High / Low 1,476 | 961
Price Date: 14-Aug-2026
Recommendation Buy
Target Price 1,818
Expected Upside 13.0%
Forecast Horizon 2 Years
Historical CAGR Not Available
1,000 Invested
Today's Value
Investment Period < 5 Years

Stock Snapshot

Post Results Return
+5.8%
Mild Positive Re-rating
1-Year Target Price
1,630
2-Year Target Price
1,818
52-Week High / Low
1,476 / 961
20-Day Return
+6.9%
Market Cap (Cr.)
38,232
Current PE
64.1
P/BV Ratio
9.7
Dividend Yield
0.0%
Industry PE
57.2

Price Performance

Basis of our Recommendation

Global Health (Medanta) is currently navigating a high-growth phase, underpinned by a robust expansion strategy that aims to significantly increase its hospital capacity across North and East India. Management's focus on enhancing its core network and transitioning developing hospitals towards profitability is critical for sustaining revenue growth. The company's five-year capex plan of INR 48,500 million is expected to bolster its competitive position, particularly in tertiary and quaternary care, which is experiencing structural demand. Vista's financial outlook reflects stable revenue growth and margins, supported by the operational momentum observed in recent quarters. However, execution risks related to large-scale projects and rising employee costs remain pertinent. The healthcare sector's favorable macro backdrop, characterized by stable pricing power and increasing insurance coverage, further supports Vista's positive outlook. Over the next 12-24 months, key opportunities include expanding the specialty mix and enhancing operational efficiency, while watchpoints include potential regulatory changes and competition in mature markets. Overall, the investment landscape appears cautiously optimistic, with a target price reflecting a 15% expected upside

👍 Why We Like This Stock

  • Robust expansion strategy with a significant capex plan to increase hospital capacity by approximately 95%
  • Strong operational momentum driven by volume-led growth and successful execution of greenfield projects
  • Stable revenue and margin outlook supported by structural demand for organized healthcare services

Things To Watch Out For

  • Execution risks associated with large-scale infrastructure projects could impact profitability timelines
  • Rising employee costs and competition in mature markets may pressure margins
  • Potential regulatory changes affecting healthcare pricing could pose risks to revenue stability

Key Parameters

Balance Sheet Strength
Conservatively Financed
Market Share
Stable
Industry Outlook
Stable
Analyst View
Strong Buy
Dividend History
Regular
FII Holdings
Reducing

Financial Snapshot

Actuals Forecast
FY24 FY25 FY26 FY27 FY28
Revenue (Cr.) 3,275 3,692 4,410 4,888 5,645
Profit Before Tax (Cr.) 626 697 714 770 930
PBT Margin 19.1% 18.9% 1619.0% 15.8% 16.5%
Net Profit (Cr.) 448 523 580 621 751
Earnings Per Share 16.7 19.5 21.6 23.1 27.9

Analyst Recommendations

Broker Recommendation Target Price Date
Anand Rathi ▲ Buy 1,400 19-May-2026
Choice Equity ▲ Buy 1,460 18-May-2026
HSBC ► Hold 1,120 21-Apr-2026
ICICI Securities ▲ Buy 1,570 17-May-2026
Jeffries ▲ Buy 1,660 03-Aug-2026
Moneycontrol ▲ Overweight nan 03-Aug-2026
Motilal Oswal ▲ Buy 1,670 01-Aug-2026
Prabhudas Liladhar ▲ Buy 1,450 18-May-2026
Consensus Recommendation ▲ Strong Buy
Consensus Target 1,665
Coverage 8 Analysts
Analysts' Viewpoint
Medanta's strategic focus on expanding its hospital network with projects in Varanasi, Guwahati, and Mumbai is expected to significantly enhance capacity and drive future growth. Analysts highlight the rapid ramp-up of the Noida facility as a positive indicator of operational momentum. However, the company faces challenges such as high capital expenditure of INR48.5 billion and potential execution risks. Regulatory changes and competition also pose threats to profitability. Despite these risks, Medanta's robust patient volume growth and strategic capacity expansions support a favorable long-term outlook.

Company Overview

Show Company Profile

Global Health Limited, together with its subsidiaries, provides healthcare services in India. The company offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, gynaecology and gynaeoncology, paediatric care, obstetrics, emergency, ENT, head and neck surgery, internal medicine, respiratory and sleep medicine, peripheral vascular and endovascular sciences, endocrinology and diabetes, rheumatology and immunology, radiology and imaging, ophthalmology, critical care, dermatology, dentistry, and dietetics and nutrition, as well as plastic, aesthetic, and reconstructive surgery. It also provides second opinion, lab tests and diagnostics, homecare and elder care services, telemedicine and air ambulance services, and e-ICU services, and health plans checkup. In addition, the company is involved in trading of pharmacy and other medical consumables; and medical and healthcare education activities. The company operates a network of hospitals under the Medanta brand. Global Health Limited was incorporated in 2004 and is based in Gurugram, India.